- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] Minimal Residual Disease Detection in Adults with Acute Lymphoblastic Leukemia By Next Generation Sequencing: Impact on Clinical Outcomes () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_727;
Of 16 patients with original Flow(-)/clonoSEQ(+) MRD, 31% (5/16) became Flow(+) and later clinically relapsed, 19% (3/16) received blinatumomab as a bridge to allogeneic hematopoietic cell transplantation (allo-HCT)...Our data supports the clinical benefit of early MRD evaluation with clonoSEQ to guide subsequent additional treatment or defer allo-HCT in MRD(-) patients. Due to the small number of patients, this analysis was mainly descriptive, and a larger patient cohort would be needed to better evaluate the clinical impact of MRD testing in adult ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] Minimal Residual Disease Detection in Adults with Acute Lymphoblastic Leukemia By Next Generation Sequencing: Impact on Clinical Outcomes () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_726;
Of 16 patients with original Flow(-)/clonoSEQ(+) MRD, 31% (5/16) became Flow(+) and later clinically relapsed, 19% (3/16) received blinatumomab as a bridge to allogeneic hematopoietic cell transplantation (allo-HCT)...Our data supports the clinical benefit of early MRD evaluation with clonoSEQ to guide subsequent additional treatment or defer allo-HCT in MRD(-) patients. Due to the small number of patients, this analysis was mainly descriptive, and a larger patient cohort would be needed to better evaluate the clinical impact of MRD testing in adult ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] Minimal Residual Disease Detection in Adults with Acute Lymphoblastic Leukemia By Next Generation Sequencing: Impact on Clinical Outcomes () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_725;
Of 16 patients with original Flow(-)/clonoSEQ(+) MRD, 31% (5/16) became Flow(+) and later clinically relapsed, 19% (3/16) received blinatumomab as a bridge to allogeneic hematopoietic cell transplantation (allo-HCT)...Our data supports the clinical benefit of early MRD evaluation with clonoSEQ to guide subsequent additional treatment or defer allo-HCT in MRD(-) patients. Due to the small number of patients, this analysis was mainly descriptive, and a larger patient cohort would be needed to better evaluate the clinical impact of MRD testing in adult ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] Minimal Residual Disease Detection in Adults with Acute Lymphoblastic Leukemia By Next Generation Sequencing: Impact on Clinical Outcomes () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_724;
Of 16 patients with original Flow(-)/clonoSEQ(+) MRD, 31% (5/16) became Flow(+) and later clinically relapsed, 19% (3/16) received blinatumomab as a bridge to allogeneic hematopoietic cell transplantation (allo-HCT)...Our data supports the clinical benefit of early MRD evaluation with clonoSEQ to guide subsequent additional treatment or defer allo-HCT in MRD(-) patients. Due to the small number of patients, this analysis was mainly descriptive, and a larger patient cohort would be needed to better evaluate the clinical impact of MRD testing in adult ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] Minimal Residual Disease Detection in Adults with Acute Lymphoblastic Leukemia By Next Generation Sequencing: Impact on Clinical Outcomes () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_723;
Of 16 patients with original Flow(-)/clonoSEQ(+) MRD, 31% (5/16) became Flow(+) and later clinically relapsed, 19% (3/16) received blinatumomab as a bridge to allogeneic hematopoietic cell transplantation (allo-HCT)...Our data supports the clinical benefit of early MRD evaluation with clonoSEQ to guide subsequent additional treatment or defer allo-HCT in MRD(-) patients. Due to the small number of patients, this analysis was mainly descriptive, and a larger patient cohort would be needed to better evaluate the clinical impact of MRD testing in adult ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Clinical, Review, Journal: Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia. (Pubmed Central) - Jan 9, 2021
Quantification of MRD with these high-sensitivity methods not only facilitates risk stratification, but also is used to determine appropriateness of intensified therapy, such as allogeneic hematopoietic cell transplant, as well as MRD-targeted therapy with blinatumomab. We review the data supporting the use of MRD quantification in ALL to guide clinical decision-making.
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Na (clinicaltrials.gov) - Jan 8, 2021
P2, N=52, Recruiting,
We review the data supporting the use of MRD quantification in ALL to guide clinical decision-making. Trial primary completion date: Dec 2020 --> Jun 2021
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
[VIRTUAL] Antibody immunotherapy treatment for adults with B‐acute lymphoblastic leukaemia–a real‐world analysis () - Jan 5, 2021 - Abstract #BSHI2020BSH-I_445;
Inotuzumab ozogamicin (Ino) is recommended as an option for treating R/R CD22‐positive B‐cell precursor ALL irrespective of Ph status...In the R/R patients, toxicity in the form of cytokine release syndrome (CRS) was observed in 50% (3 of 6) of patients receiving Blina, and two thirds (67%) of these were grade 3/4; requiring Tocilizumab...A significant proportion of patients achieve morphological remission after 1 cycle substantiating the efficacy of these therapies as previously reported.1,2 Real‐world toxicity also appears comparable. Larger cohorts are needed to fully address the safety and efficacy of these agents in unselected patient cohorts.
- |||||||||| [VIRTUAL] Relapsed acute lymphoblastic leukaemia diagnosed using femoral head histology () - Jan 5, 2021 - Abstract #BSHI2020BSH-I_166;
She was treated with FLAG‐IDA, followed by blinatumomab due to ongoing minimal residual disease (MRD) positivity, before undergoing an allogenic transplant...The patient received FLAG‐IDA, inotuzumab and gemtuzumab, following which he was in remission...The patient was re‐treated with nelarabine, cyclophosphamide and etoposide with high‐dose methotrexate...From literature there are only case reports of relapsed ALL presenting this way and the exact number of patients with evidence of disease in the femoral head is unknown. We would recommend as a result of our experience always sending bone specimens for histology in patients with a history of ALL undergoing joint replacement surgery.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 5, 2021
P1, N=44, Recruiting,
We would recommend as a result of our experience always sending bone specimens for histology in patients with a history of ALL undergoing joint replacement surgery. Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial, Combination therapy: EWALL-Ph-03: Study in Adult Ph-positive ALL (clinicaltrials.gov) - Dec 29, 2020
P2, N=180, Not yet recruiting,
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Clinical, Review, Journal: Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy. (Pubmed Central) - Dec 23, 2020
The decision to incorporate consolidative allogeneic HCT into front-line therapy should be primarily guided by MRD status and the ALL regimen utilized. Targeted immunotherapies result in high MRD-negative CR rates, allowing more adults with relapsed/refractory ALL to be successfully bridged to HCT; early incorporation of these therapies may also prove valuable in reducing the need for HCT in the front-line setting by increasing MRD negative CR rates.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Clinical, Review, Journal: Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. (Pubmed Central) - Dec 23, 2020
A number of advances in ALL have resulted in dramatic changes to the treatment landscape and therapeutic options both at the time of diagnosis and in salvage. These findings are reshaping our treatment paradigms throughout the course of disease.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: Advances in Supportive Care for Acute Lymphoblastic Leukemia. (Pubmed Central) - Dec 23, 2020
The hepatic injury incurred by inotuzumab, and the vascular toxicity of tyrosine kinase inhibitors, other relatively novel agents, require subspecialist intervention and multidisciplinary care...Lastly, although there have been few changes in the applications of growth factor, antimicrobial prophylaxis, and management of neuropathy, these encompass exceedingly important aspects of care. While the rapidly changing treatment paradigms for acute lymphoblastic leukemia have transformed leukemia-specific outcomes, treatment emergent toxicities have forced much necessary attention to better definitions of these toxicities and on improving supportive care guidelines in acute lymphoblastic leukemia.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Journal: Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity. (Pubmed Central) - Dec 20, 2020
It is the first time that such cells are induced by introducing the bispecific antibody drug (blinatumomab) and feeder cells (normal B cells and irradiated B cell originated lymphoma cells) to the traditional T cells culture system...This work further confirmed the feasibility of rapid induction and expansion of large amounts of human T cells in vitro by using bispecific antibodies and feeder cells. This strategy could also be used for other immune cells rapid expansion and help to improve the quality of these expanded immune cells for adoptive transfusion.
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Clinical, Journal: Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. (Pubmed Central) - Dec 18, 2020
Multiple immune-based therapies have demonstrated considerable efficacy in the setting of relapsed or refractory (R/R) disease, including CD19 targeting with blinatumomab and tisagenlecleucel and CD22 targeting with inotuzumab ozogamicin. These agents are now under investigation by the Children's Oncology Group (COG) in clinical trials for newly diagnosed B-ALL, with integration into standard chemotherapy regimens based on clinically and biology-based risk stratification as well as disease response.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Journal: How we infuse blinatumomab. (Pubmed Central) - Dec 16, 2020
These agents are now under investigation by the Children's Oncology Group (COG) in clinical trials for newly diagnosed B-ALL, with integration into standard chemotherapy regimens based on clinically and biology-based risk stratification as well as disease response. No abstract available
- |||||||||| Removab (catumaxomab) / NeoPharm, Trion, Blincyto (blinatumomab) / Astellas, Amgen
Review, Journal: Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. (Pubmed Central) - Dec 16, 2020
No abstract available Dual TAAs targeting BsAbs represent a valuable class of biologics and early stage clinical studies have demonstrated promising anti-tumor efficacy in both hematologic malignancies and solid tumors.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: Recent updates for antibody therapy for acute lymphoblastic leukemia. (Pubmed Central) - Dec 10, 2020
Compared with chemotherapy, the application of an antibody-drug conjugates (ADC) called inotuzumab ozogamicin in relapsed or refractory (R/R) CD22...Similarly, blinatumomab, the first FDA-approved bispecific antibody (BsAb), produced a 44% complete response rate and an overall median survival of 7.7 months in a widely treated ALL population...Meanwhile the combination of antibody-based therapy with traditional standard of care (SOC) chemotherapy, chimeric antigen receptor (CAR) T-cell therapy and HSCT is also a challenge. Here, we will review some important milestones of antibody-based therapies, including combinational strategies, and antibodies under clinical development for ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Clinical, Review, Journal, CAR T-Cell Therapy: Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease. (Pubmed Central) - Dec 3, 2020
In addition, suitability of the patient for hematopoietic stem cell transplant (HSCT) as well as patient preference must also be considered. This review will focus on factors to weigh when choosing an agent in the setting of R/R disease and important challenges moving forward.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: Observational Study of Blinatumomab (clinicaltrials.gov) - Nov 30, 2020
P=N/A, N=360, Recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2020 --> Aug 2021 Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] COMMON HIGH RISK B ACUTE LYMPHBLASTIC LEUKEMIA IN ADULTS WITH TREATMENT WITH BLINATUMOMAB PRE-BONE MARROW TRANSPLANTATION: A CASE REPORT () - Nov 26, 2020 - Abstract #HEMO2020HEMO_817;
We highlight the use and efficiency of blinatomumab, a monoclonal antibody that is still little used in Brazil due to its high cost, as a therapeutic option to eliminate DRM. The patient had a satisfactory response after the first cycle, reaching the goal of negative DRM, and was referred to BMT in the best conditions desired by the literature, but she had an early relapse and was treated with another new monoclonal anti-CD22 antibody (inotuzumab) associated with less intensive chemotherapy, without success.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
[VIRTUAL] THE USE OF TARGET THERAPY IN A PEDIATRIC PATIENT WITH REFLATORY ALL-B: CASE REPORT () - Nov 26, 2020 - Abstract #HEMO2020HEMO_286;
The development of this agent in children has been delayed, with the first pediatric studies started in 2016–2017. The most reported adverse effects are, hepatic veno-oculusive disease, mainly after bone marrow transplantation, myelosuppression / cytopenias, infusion reactions, Tumor lysis syndrome and prolongation of the QT interval, although the studies show good responses to medication and good tolerance during its use.
- |||||||||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
[VIRTUAL] LLA-B, PHILADELPHIA + RECURRENT AFTER BONE MARROW TRANSPLANTATION, WITH RESPONSE TO PONATINIBE: CASE REPORT () - Nov 26, 2020 - Abstract #HEMO2020HEMO_279;
At the end of the first blinatumomab cycle, she presented negative DRM...He switched desatinib to ponatinib 30 mg / day, with prednisone and weekly doses of vincristine on 06/13/2020, without complications...The prognosis of patients with recurrent Ph + ALL after allogeneic BMT is reserved, and few therapeutic options are viable, including: donor lymphocyte infusion, conventional chemotherapy, immunotherapy (blinatomumab, inotuzumab ozogamycin), therapy with CAR-T cells, according to TMO allogeneic and exclusive supportive care, but the overall survival rates for this population at 3 years are less than 25%... Patient with ALL-B, Ph +, relapsed after allogeneic bone marrow BMT compatible, refractory to blinatomumab and conventional chemotherapy, which achieved a rapid response with the use of ponatinib associated with corticosteroids and vincristine, allowing for a second haploidentic BMT.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] BLINATUMUMABE IN ADULT RECRIVED / REFRACTORY ACUTE LYMPHIDE LEUKEMIA WITH HIGH TUMOR LOAD: CASE REPORT () - Nov 26, 2020 - Abstract #HEMO2020HEMO_243;
Fifteen days after the end of the treatment, the Immunophenotyping was repeated and the patient had 0.003% of blasts, presenting for the first time since the beginning of the treatment, DRM Negative. Although it is the report of only one case, the data presented here suggest that the use of Blinatumumab in adult patients with refractory / relapsed ALL with high tumor burden is a viable therapeutic alternative.
|
